Empery Asset Management LP Buys Shares of 842,669 Lantern Pharma Inc. $LTRN

Posted by George Bondi on Aug 22nd, 2026

Empery Asset Management LP purchased a new stake in Lantern Pharma Inc. (NASDAQ:LTRN – Free Report) during the second quarter, according to its most recent filing with the SEC. The firm purchased 842,669 shares of the company’s stock, valued at approximately $3,513,930,000. Lantern Pharma accounts for 4.1% of Empery Asset Management LP’s portfolio, making the stock its 7th biggest holding. Empery Asset Management LP owned about 0.07% of Lantern Pharma at the end of the most recent quarter.

Other large investors have also recently made changes to their positions in the company. Susquehanna International Group LLP purchased a new stake in shares of Lantern Pharma during the 3rd quarter worth $170,000. BlackRock Inc. purchased a new position in Lantern Pharma in the second quarter valued at about $93,000. Bank of New York Mellon Corp purchased a new position in Lantern Pharma in the second quarter valued at about $89,000. Vanguard Group Inc. raised its holdings in Lantern Pharma by 5.6% in the third quarter. Vanguard Group Inc. now owns 384,041 shares of the company’s stock worth $1,671,000 after purchasing an additional 20,321 shares in the last quarter. Finally, Two Sigma Investments LP bought a new position in Lantern Pharma in the third quarter worth about $70,000. 28.62% of the stock is owned by institutional investors.

Analyst Upgrades and Downgrades

A number of research firms have recently weighed in on LTRN. Weiss Ratings upgraded shares of Lantern Pharma from a “sell (e+)” rating to a “sell (d-)” rating in a report on Wednesday, July 29th. Wall Street Zen downgraded shares of Lantern Pharma from a “hold” rating to a “sell” rating in a research note on Saturday, August 15th. One research analyst has rated the stock with a Sell rating, Based on data from MarketBeat.com, the stock has an average rating of “Sell”.

Get Our Latest Stock Analysis on Lantern Pharma

Lantern Pharma Trading Up 2.2%

Shares of Lantern Pharma stock opened at $2.34 on Friday. The firm’s 50 day simple moving average is $3.17 and its two-hundred day simple moving average is $2.83. The firm has a market capitalization of $29.91 million, a price-to-earnings ratio of -1.44 and a beta of 2.34. Lantern Pharma Inc. has a 12-month low of $1.11 and a 12-month high of $4.70.

Lantern Pharma (NASDAQ:LTRN – Get Free Report) last issued its quarterly earnings results on Friday, August 14th. The company reported ($0.57) EPS for the quarter, missing analysts’ consensus estimates of ($0.38) by ($0.19).

Lantern Pharma Company Profile

(Free Report)

Lantern Pharma, Inc is a clinical-stage oncology company leveraging artificial intelligence (AI) and machine learning to accelerate the discovery and development of targeted cancer therapies. Headquartered in Dallas, Texas, Lantern Pharma’s proprietary RADR® platform integrates large-scale genomic, transcriptomic and chemical data to identify novel drug candidates and predict patient populations most likely to benefit from treatment.

The company’s pipeline focuses on molecules designed to address cancers with high unmet medical need.